Shanghai Allist Pharmaceuticals Past Earnings Performance
Past criteria checks 6/6
Shanghai Allist Pharmaceuticals has been growing earnings at an average annual rate of 84.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 67% per year. Shanghai Allist Pharmaceuticals's return on equity is 26.7%, and it has net margins of 40.5%.
Key information
84.5%
Earnings growth rate
85.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 67.0% |
| Return on equity | 26.7% |
| Net Margin | 40.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Allist Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,204 | 1,297 | 1,419 | 297 |
| 30 Jun 24 | 2,846 | 1,092 | 1,317 | 301 |
| 31 Mar 24 | 2,485 | 915 | 1,215 | 282 |
| 31 Dec 23 | 2,018 | 644 | 1,051 | 281 |
| 30 Sep 23 | 1,621 | 487 | 882 | 230 |
| 30 Jun 23 | 1,239 | 312 | 736 | 188 |
| 31 Mar 23 | 956 | 188 | 613 | 190 |
| 31 Dec 22 | 791 | 131 | 524 | 176 |
| 30 Sep 22 | 560 | -63 | 489 | 175 |
| 30 Jun 22 | 709 | 123 | 432 | 197 |
| 31 Mar 22 | 604 | 40 | 399 | 213 |
| 31 Dec 21 | 530 | 18 | 367 | 201 |
| 30 Sep 21 | 488 | 29 | 327 | 202 |
| 30 Jun 21 | 122 | -255 | 278 | 174 |
| 31 Mar 21 | 37 | -289 | 233 | 160 |
| 31 Dec 20 | 1 | -311 | 185 | 175 |
| 30 Sep 20 | 1 | -354 | 199 | 186 |
| 31 Mar 20 | 1 | -299 | 250 | 212 |
| 31 Dec 19 | 1 | -398 | 235 | 160 |
| 31 Dec 18 | 5 | -97 | 22 | 91 |
| 31 Dec 17 | 8 | -39 | 20 | 36 |
Quality Earnings: 688578 has high quality earnings.
Growing Profit Margin: 688578's current net profit margins (40.5%) are higher than last year (30%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688578 has become profitable over the past 5 years, growing earnings by 84.5% per year.
Accelerating Growth: 688578's earnings growth over the past year (166.3%) exceeds its 5-year average (84.5% per year).
Earnings vs Industry: 688578 earnings growth over the past year (166.3%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 688578's Return on Equity (26.7%) is considered high.